CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
AccurEdit Therapeutics
Company Type: Therapeutic development
Main focus: Developing novel in vivo genetic medicines
Company stage: Clinical
Diseases: ATTR amyloidosis and other inherited and metabolic disorders
Genome-editing tool: CRISPR
Funding stage: Venture Capital-Backed
Location: Suzhou, Jiangsu, China
Website: https://www.accuredit.com/
Pipeline: https://www.accuredit.com/45/
Partners:
AccurEdit Therapeutics is a clinical-stage biotechnology company based in Jiangsu, China that is focused on the development of novel in vivo gene editing therapies to treat various inherited and acquired diseases. The company is focused on developing safe, effective, and targeted gene-editing and delivery systems, and has developed a proprietary end-to-end gene-editing technology platform that focuses on RNA synthesis, gene editing, and delivery. The company's pipeline features a clinical stage trial for ART001, a CRISPR based gene-editing candidate designed to treat ATTR amyloidosis.
